Nasdaq:KEQU
KEWAUNEE SCIENTIFIC CORP /DE/
A specialized manufacturer of scientific instrumentation delivering high-precision analytical solutions for life sciences and industrial research markets.
Key Metrics
Investment Thesis
Bull Case
KEW offers exposure to a critical niche in scientific instrumentation with a demonstrated ability to generate positive operating profit of $17.8M. The recent revenue recovery suggests resilience in core product demand, and the company maintains a positive free cash flow conversion despite heavy capital expenditures on acquisitions totaling $28.7M.
Bear Case
Investors should be wary of the deteriorating earnings trend from 2024 to 2025 and the substantial accumulated deficit in retained earnings of $58.9M. The high debt load combined with negative net change in cash raises concerns about liquidity and the ability to fund future growth without dilution or distress.
About KEWAUNEE SCIENTIFIC CORP /DE/
KEW Scientific Corp designs and manufactures high-performance scientific instruments and components primarily serving life sciences, materials science, and research sectors. The company leverages its proprietary technology to deliver specialized solutions for global laboratories and industrial R&D departments. With a focus on innovation and precision engineering, the firm addresses critical needs in analytical chemistry, spectroscopy, and advanced material characterization.
Analysis
Management Discussion
While the company successfully rebounded to $240.5M in revenue for 2025, profitability remains volatile with net income dropping from a peak of $19.1M in 2024 to $11.6M last year. The balance sheet shows substantial debt levels relative to equity, and the company has relied on financing cash flows of $7.4M to offset significant investing outflows.
Industry Overview
The global scientific instrumentation market is characterized by specialized demand for precision equipment used in pharmaceutical R&D, academic research, and industrial quality control. Companies in this space face pressure from rapid technological shifts but benefit from long product lifecycles and high switching costs once laboratories are equipped.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $219.5M | $203.8M | $240.5M |
| Cost of Revenue | $183.9M | $151.7M | $171.6M |
| Gross Profit | $35.6M | $52.1M | $68.9M |
| Operating Expenses | $30.2M | $33.8M | $51.1M |
| Operating Income | $5.4M | $18.3M | $17.8M |
| R&D | $1.0M | $920.0K | $919.0K |
| Stock-Based Comp | $886.0K | $1.0M | $1.4M |
| D&A | — | — | $4.8M |
| Depreciation | $2.9M | $3.1M | $4.0M |
| Other OpEx | $29.2M | $32.9M | $50.2M |
| Non-Operating Income | $-866.0K | $-5.2M | $-3.0M |
| Interest Expense | $1.7M | $1.8M | — |
| Pre-Tax Income | $4.5M | $13.1M | $14.8M |
| Income Tax | $3.1M | $-5.9M | $3.2M |
| Continuing Ops | $1.4M | $19.1M | $11.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.4M | $19.1M | $11.6M |
| Minority Interest | $621.0K | $304.0K | $178.0K |
| Net to Common | $738.0K | $18.8M | $11.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $87.9M | $96.8M | $118.4M |
| Cash & Equivalents | $8.1M | $23.3M | $14.9M |
| Accounts Receivable | $46.1M | $45.1M | $62.4M |
| Inventory | $21.9M | $20.7M | $32.8M |
| Prepaid Expenses | $6.1M | $5.1M | $6.0M |
| Other Current Assets | $5.7M | $2.7M | $2.2M |
| Long-Term Assets | $31.0M | $37.9M | $76.3M |
| PP&E (Net) | $16.4M | $17.6M | $23.2M |
| Intangibles | — | — | $17.8M |
| Goodwill | — | — | $12.5M |
| Operating Leases | $9.2M | $7.5M | $13.0M |
| Other LT Assets | $5.4M | $12.8M | $9.8M |
| Total Assets | $118.9M | $134.8M | $194.7M |
| Current Liabilities | $40.1M | $40.8M | $53.7M |
| Accounts Payable | $23.6M | $23.3M | $27.0M |
| Current Debt | — | — | $3.0M |
| Current Leases | $2.0M | $2.1M | $3.3M |
| Deferred Revenue | $4.1M | $4.4M | $6.1M |
| Other Current Liab | $10.4M | $11.0M | $14.3M |
| Long-Term Liabilities | $40.4M | $37.8M | $74.7M |
| Long-Term Debt | — | — | $34.7M |
| LT Operating Leases | $7.1M | $5.4M | $8.8M |
| Other LT Liab | $33.2M | $32.3M | $31.2M |
| Total Liabilities | $80.4M | $78.6M | $128.4M |
| Shareholders' Equity | $38.5M | $56.2M | $66.2M |
| Retained Earnings | $28.8M | $47.5M | $58.9M |
| AOCI | $-3.4M | $-3.4M | $-3.8M |
| Treasury Stock | $53.0K | $2.1M | $3.6M |
| Total L&E | $118.9M | $134.8M | $194.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.4M | $19.1M | $11.6M |
| Non-Cash Adjustments | $-3.4M | $1.5M | $-1.5M |
| Working Capital Changes | $-1.8M | $-983.0K | $4.7M |
| Cash from Operations | $-3.8M | $19.6M | $14.8M |
| Cash from Investing | $-4.1M | $-4.4M | $-30.9M |
| Debt Issuances | $0 | $202.0K | — |
| Debt Repayments | $121.0K | $88.0K | — |
| Share Buybacks | — | $2.0M | $1.6M |
| Cash from Financing | $14.9M | $-3.0M | $7.4M |
| FX Effect | $-72.0K | $-54.0K | $-67.0K |
| Net Change in Cash | $6.9M | $12.1M | $-8.8M |
| Beginning Cash | $6.9M | $13.8M | $25.9M |
| Ending Cash | $13.8M | $25.9M | $17.2M |
Frequently Asked Questions
How does KEWAUNEE SCIENTIFIC CORP /DE/ make money?
1) Core Instrumentation: Sales of proprietary optical and analytical instruments driving $240.5M in revenue. 2) Components and Custom Solutions: Manufacturing of specialized parts and tailored systems for specific client R&D workflows. 3) Aftermarket Services: Maintenance, calibration, and replacement parts generating recurring revenue streams.
What are the main risks for KEQU?
1) Revenue Volatility: Recent decline from 2024 highs followed by a recovery suggests sensitivity to cyclical R&D spending or macroeconomic headwinds. 2) High Debt Burden: Total liabilities of $128.4M against $66.2M in equity indicates significant leverage with $34.7M in long-term debt. 3) Cash Flow Pressure: Significant investing outflows of $30.9M and net cash decline of $8.8M could constrain future operational flexibility.
What is KEQU's competitive advantage?
1) Proprietary Technology: Patented optical designs and sensor integration creating high barriers to entry in niche analytical markets. 2) Specialized Niche Focus: Deep domain expertise serving specialized scientific communities less attractive to large conglomerates. 3) R&D Intensity: Continued investment in engineering capabilities, evidenced by over $1M annual research spend.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.